Sermorelin
Also known as: GRF 1-29
Molecular Identifiers
Molecular Formula
C149H246N44O42S
CAS Number
86168-78-7
PubChem CID
16132413Molecular Weight
3357.96 Da
Overview
GHRH analog with gentle GH stimulation. Suitable for long-term protocols. Good option for anti-aging research with a conservative profile.
The main clinical interest around sermorelin is stimulating endogenous growth hormone (GH) secretion from the pituitary in a physiological way — preserving natural negative feedback via somatostatin, unlike exogenous recombinant GH replacement. The sought effects are support for REM sleep, recovery, body composition, and quality of life in adults with age-related decline of somatotropic function.
It was originally FDA-approved as Geref (1990) for the diagnosis and treatment of GH deficiency in children, but its commercial production was discontinued in the U.S. in 2008. Today it circulates mostly as off-label use through compounding pharmacies in anti-aging and functional endocrinology medicine, in evening 12+ week subcutaneous protocols, often combined with GHRP peptides (ipamorelin, GHRP-2) for synergistic stimulation. WADA lists GHRH and its analogs as substances prohibited in sports competition.
It corresponds to fragment 1-29 of native human GHRH — the minimal portion that retains full biological activity on the GHRH receptor in the anterior pituitary.
Among GHRH analogs, sermorelin is the most "natural" — native human sequence, with no modifications to extend half-life — and therefore the shortest-acting: it contrasts with Mod GRF 1-29 (CJC-1295 without DAC, more stable), with CJC-1295 with DAC (weekly dosing via albumin binding), and with tesamorelin (FDA-approved modified analog for HIV lipodystrophy). It acts on the GHRH receptor and is therefore often combined with a GHRP (ipamorelin, GHRP-2, GHRP-6, or hexarelin) or contrasted with MK-677, which mimics ghrelin via the oral route.
YADAIFTNSYRKVLGQLSARKLLQDIMSR Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg Half-life
~10-20 minutes
Administration Route
Subcutaneous
Category
GH Secretagogues
Mechanism of Action
- Native GHRH analog (fragment 1-29)
- Physiological stimulation of GH secretion
- Preserves natural negative feedback
- Promotes REM sleep and recovery
Dosage Protocol
Data compiled from the literature. This does not constitute medical advice.
| Parameter | Value |
|---|---|
| Dose | 200-500 mcg per injection |
| Frequency | Once daily |
| Timing | Before bedtime |
| Duration | 12+ weeks |
Reported Side Effects
Adverse effects described in the literature. Severity and frequency vary between individuals.
- Facial flushing
- Headache
- Dizziness
- Injection site pain
- Drowsiness
Product Properties
| Purity | >99% |
| Appearance | White lyophilized powder |
| Solubility | Soluble in water and bacteriostatic water |
| Source | Solid-phase peptide synthesis (SPPS) |
| Storage | Lyophilized: -20°C for up to 2 years, 2-8°C for up to 6 months. Reconstituted: 2-8°C for up to 4 weeks. Protect from light and moisture. Avoid repeated freeze-thaw cycles. |
Presentations & Preparation
Vials of Sermorelin found in the research market:
Reconstitution
- Diluent: Bacteriostatic water
- Volume: 2 ml per 5 mg vial
- Slowly inject the diluent against the vial wall
- Gently swirl until fully dissolved
- Never shake
Storage
- Lyophilized: Refrigerated 2-8°C
- Reconstituted: Refrigerated 2-8°C (up to 30 days)
- Protect from direct light
- Do not freeze after reconstitution
Scientific Studies
Published studies on Sermorelin.
Sermorelin: A better approach to management of adult-onset growth hormone insufficiency?
Walker RF
Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women
Khorram O, Laughlin GA, Yen SS
Related Peptides
CJC-1295 with DAC
1-2 mg per week · Once per week
CJC-1295 sem DAC
100-200 mcg per injection · 2-3 times daily
GHRP-2
100-300 mcg per injection · 2-3 times per day
GHRP-6
100-300 mcg per injection · 2-3 times per day
Hexarelin
200-300 mcg per injection · 2-3 times per day
Ipamorelin
200-300 mcg per injection · 2-3 times daily